Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares stood at 1.7 million during the last session, with the company’s beta value hitting 0.80. At the close of trading, the stock’s price was $0.84, to imply a decrease of -5.56% or -$0.05 in intraday trading. The GALT share’s 52-week high remains $4.27, putting it -408.33% down since that peak but still an impressive 13.1% since price per share fell to its 52-week low of $0.73. The company has a valuation of $49.47M, with an average of 1.93 million shares in intraday trading volume over the past 10 days and average of 476.04K shares over the past 3 months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
After registering a -5.56% downside in the last session, Galectin Therapeutics Inc (GALT) has traded red over the past five days. The 5-day price performance for the stock is -60.85%, and -70.15% over 30 days. With these gigs, the year-to-date price performance is -50.01%. Short interest in Galectin Therapeutics Inc (NASDAQ:GALT) saw shorts transact 5.52 million shares and set a 42.37 days time to cover.
Galectin Therapeutics Inc (GALT) estimates and forecasts
Looking at statistics comparing Galectin Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Galectin Therapeutics Inc (GALT) shares are -62.62% down over the last 6 months, with its year-to-date growth rate lower than industry average at 1.35% against 16.40%.
GALT Dividends
Galectin Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Galectin Therapeutics Inc insiders hold 30.95% of total outstanding shares, with institutional holders owning 15.77% of the shares at 22.85% float percentage. In total, 15.77% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 2.12 million shares (or 3.4143% of shares), all amounting to roughly $4.78 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 1.56 million shares, or about 2.5232% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.53 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Galectin Therapeutics Inc (GALT) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.25 shares. This is just over 1.99% of the total shares, with a market valuation of $1.05 million. Data from the same date shows that the other fund manager holds a little less at 670.16, or 1.07% of the shares, all valued at about 0.56 million.
